Harmony Biosciences Holdings Inc
NASDAQ:HRMY 4:00:00 PM EDT
| Market Cap (Intraday) | 1.65B |
| Current PE | 12.79 |
| Forward PE | 9.71 |
| 2yr Forward PE | 7.22 |
| 10-Day MA | $29.83 |
| 50-Day MA | $31.85 |
| 200-Day MA | $31.46 |
Harmony Biosciences Holdings Inc Stock, NASDAQ:HRMY
630 West Germantown Pike, Suite 215, Plymouth Meeting, Pennsylvania 19462
United States of America
Phone: +1.484.539.9800
Number of Employees: 246
Description
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of therapies for the treatment of neurological disorders. Its product, WAKIX, is a molecule with a novel mechanism of action designed to increase histamine signaling in the brain by binding to H3 receptors. The company was founded by Jeffrey S. Aronin on July 25, 2017 and is headquartered in Plymouth Meeting, PA.